Elixirgen Scientific Japan | Top CDMOs in APAC 2023
Pharma Tech Outlook

Pharma Tech Outlook

Elixirgen Scientific Japan
Setting the Standard

Elixirgen Scientific Japan: Setting the Standard: Elixirgen Scientific’s mRNA CDMO Excellence

Motoki Azuma, President and Daisuke Takagi, Vice President, Elixirgen Scientific JapanMotoki Azuma, President and Daisuke Takagi, Vice President
Elixirgen Scientific Japan, a Japanese subsidiary of a renowned US biotechnology company, is accelerating the drug discovery research and development in pharmaceutical industries through its advancements in stem cell-based technologies and mRNA manufacturing know-hows. The firm uses innovative technologies, expediting the process of drug discovery and development to enhance human well-being. Elixirgen Scientific provides high-quality induced pluripotent stem cell (iPSC) differentiation technology and high-quality mRNA to research institutions, pharmaceutical organizations, and biomedical enterprises, playing a crucial role in increasing efficiency in medical research.

Elixirgen Scientific delivers highly efficient, adaptable biomedical research tools, focusing on two key areas: induced pluripotent stem (iPS) applications and its contract development and manufacturing organization (CDMO) operations within the mRNA field. It also provides mRNA CDMO services to support drug discovery, providing affordable GMP mRNA solutions to improve quality of life. Elixirgen Scientific’s commitment to innovation and efficiency underscores its goal to transform drug discovery process.

The firm’s CDMO business was launched in Japan and the wider APAC region as a direct response to the COVID-19 pandemic due to the worldwide shortage of high-quality mRNA.

Elixirgen Scientific provides mRNA to pharmaceutical companies for research and clinical trials, which constitutes the central pillar of its CDMO business.

The firm’s state-of-the-art facilities comply with CGMP regulatory regulations, offering research-and clinical-grade mRNA while exceeding industry standards in research-grade product quality.

“Our journey commenced two years ago, during which we successfully delivered more than 250 mRNAs to over 10 organizations,” says Motoki Azuma, president of Elixirgen Scientific. Each member of its team has extensive experience in manufacturing over 100 mRNA products.

Elixirgen Scientific’s commitment to exceptional customer service has consistently garnered high praise for its products’ quality and timely delivery. Notably, the company has reduced delivery time, which is critical in an era when scientists frequently order high-quality mRNAs for their projects.


Our journey commenced two years ago, during which we successfully delivered more than 250 mRNAs to over 10 organizations

The company takes pride in receiving a national grant from the Ministry of Economy, Trade, and Industry, demonstrating its alignment with the government’s objectives to improve the platform for vaccination against future global outbreaks. Using the national grant, the company has increased its investment to expand its manufacturing facilities. Elixirgen Scientific also contributes to public safety and facilitates strategic investments, expressing its gratitude for this recognition while looking forward to a bright future.

Elixirgen Scientific’s team of experienced scientists, knowledge of high-quality mRNA production, and approach to process development contribute to its position as an industry leader. The firm consistently receives recognition from its customers, with many acknowledging its product’s exceptional quality as compared to competitors.

Elixirgen Scientific Japan News

Elixirgen Scientific, Inc. Achieves ISO 9001:2015 Certification, Strengthening Commitment to Quality, Excellence in Biotechnology

Baltimore – Elixirgen Scientific, Inc., a leading biotechnology company dedicated to advancing drug discovery and transforming cell therapy using iPSC technology, has officially obtained ISO 9001:2015 certification. This accreditation, established by the International Organization for Standardization (ISO), is a globally recognized standard designed to verify that a company's products and services meet customer needs through an effective Quality Management System. The attainment of this certification underscores Elixirgen Scientific's ongoing commitment to enhancing quality processes across all facets of its operations, implementing effective risk management, pursuing continuous improvement, and adhering to stringent regulatory requirements. By achieving ISO 9001:2015 certification, Elixirgen Scientific ensures that its iPSC-derived cells and services are developed and delivered in accordance with the highest standards of quality management, thereby significantly enhancing their reliability and efficacy for advanced research and therapeutic applications.

The ISO 9001 certification serves as a testament to Elixirgen Scientific's dedication to customer satisfaction, the delivery of exceptional products and services, and the maintenance of a robust quality management system, solidifying its position as a trailblazer in the field of biotechnology. Elixirgen Scientific's groundbreaking solutions, such as Quick-Glia™ iPSC-derived astrocytes and custom differentiation services, aim to advance research on neuroinflammatory and neurodegenerative diseases by improving the relevance and efficiency of drug development processes.

Elixirgen Scientific, Inc. underwent a comprehensive audit that thoroughly examined the entire product lifecycle management process, services and product design, and development practices. The initial audit was conducted by QAS International, a reputable independent certification authority. The successful issuance of the ISO 9001:2015 certification followed this rigorous evaluation. Continuous surveillance audits by QAS International will ensure ongoing compliance with ISO 9001 standards and the implementation of best practices, fostering continuous enhancement of products, services, and customer satisfaction.

Top 10 CDMOs in APAC - 2023

Company
Elixirgen Scientific Japan

Management
Motoki Azuma, President and Daisuke Takagi, Vice President

Description
Elixirgen Scientific is a global leader in induced pluripotent stem cell (iPSC) differentiation technology and mRNA manufacturing, with a mission to advance science and medicine with fast, functional, and scalable iPSC differentiation products and services and high quality mRNA services.